- Home
- INCY
INCY
Incyte Corp.
as 04-18-2025 12:37pm EST
Incyte focuses on the discovery and development of small-molecule drugs. The firm's leading drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis and 2022 for vitiligo. Incyte's pipeline includes a broad array of oncology and dermatology programs.
| Founded: | 1991 | Country: | United States |
| Employees: | N/A | City: | WILMINGTON |
| Market Cap: | 13.4B | IPO Year: | 1993 |
| Target Price: | $74.00 | AVG Volume (30 days): | 2.3M |
| Analyst Decision: | Hold | Number of Analysts: | 20 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | 0.15 | EPS Growth: | -94.34 |
| 52 Week Low/High: | $50.35 - $83.95 | Next Earning Date: | 04-29-2025 |
| Revenue: | $4,241,216,999 | Revenue Growth: | 14.76% |
| Revenue Growth (this year): | 12.21% | Revenue Growth (next year): | 9.20% |
Stock Insider Trading Activity of Incyte Corp. (INCY)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Flannelly Barry P | INCY | EVP & General Manager US | Mar 14 '25 | Sell | $67.80 | 19,807 | $1,340,655.93 | 52,913 | |
| Denton Sheila A. | INCY | EVP & General Counsel | Mar 4 '25 | Sell | $69.99 | 599 | $41,924.01 | 25,848 | |
| Denton Sheila A. | INCY | EVP & General Counsel | Feb 26 '25 | Sell | $74.07 | 14,069 | $1,042,135.78 | 25,848 |
Latest Incyte Corp. News
INCY Breaking Stock News: Dive into INCY Ticker-Specific Updates for Smart Investing
MT Newswires
2 days ago
BofA Adjusts Price Target on Incyte to $87 From $86, Keeps Buy Rating
StockStory
4 days ago
Immuno-Oncology Stocks Q4 In Review: Exact Sciences (NASDAQ:EXAS) Vs Peers
MT Newswires
8 days ago
Incyte Faces Limited Exposure From Tariffs on Dual Sourcing, UBS Says
Business Wire
9 days ago
Incyte to Report First Quarter Financial Results
Business Wire
11 days ago
Incyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
StockStory
12 days ago
Immuno-Oncology Stocks Q4 Highlights: Incyte (NASDAQ:INCY)
Zacks
15 days ago
How to Boost Your Portfolio with Top Medical Stocks Set to Beat Earnings
Simply Wall St.
16 days ago
Exploring 3 High Growth Tech Stocks In The US Market
Compare INCY vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "INCY Incyte Corp. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.